3-(5-甲基-1,2,4-恶二唑-3-基)吡啶 | 10350-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(5-甲基-1,2,4-恶二唑-3-基)吡啶
• 英文名称: 3-<3>Pyridyl-5-methyl-oxadiazol-1,2,4
• 英文别名: 3-(5-Methyl-1,2,4-oxadiazol-3-yl)pyridin；3-(5-methyl-[1,2,4]oxadiazol-3-yl)-pyridine；3-(methyl-[1,2,4]oxadiazol-3-yl)-pyridine；3-(Methyl-[1,2,4]oxadiazol-3-yl)-pyridin；5-Methyl-3-(3-pyridyl)-1,2,4-oxadiazole；5-methyl-3-pyridin-3-yl-1,2,4-oxadiazole
• CAS: 10350-69-3
• 化学式: C₈H₇N₃O
• mdl: MFCD00264571
• 分子量: 161.163
• InChiKey: UPZLTNFTZQZHHR-UHFFFAOYSA-N

物化性质

• 熔点：
  107-111 °C
• 沸点：
  315.4±44.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙酸酐 作用下， 生成 3-(5-甲基-1,2,4-恶二唑-3-基)吡啶
  参考文献：
  名称：

  1：2：4-恶二唑的合成

  摘要：

  DOI：

  10.1039/jr9540004251

文献信息

• [EN] OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE, QUI SONT DES DÉRIVÉS [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014057435A1

  公开（公告）日：2014-04-17

  The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及公式(I)中的[ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-甲酮衍生物，其中R和环A1、A2和A3如描述中所述，以及其药用盐，其制备方法，含有一个或多个公式(I)化合物的药物组合物，以及它们作为药物的用途，特别是作为促进睡眠荷尔蒙受体拮抗剂的用途。
• Cyanothiophene derivatives, compositions containing such compounds and methods of use
  申请人：——

  公开号：US20040097552A1

  公开（公告）日：2004-05-20

  The present invention addresses substituted cyanothiophene derivatives of the formula I: 1 as well as compositions containing such compounds and methods of treatment. The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose providing a treatment of diabetes.

  本发明涉及式I的取代氰基噻吩衍生物，以及含有这种化合物的组合物和治疗方法。本发明中的化合物是胰高血糖素拮抗剂。这些化合物阻断了胰高血糖素在其受体上的作用，从而降低血浆葡萄糖水平，提供糖尿病的治疗。
• [EN] QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE QUINOLIZIDINONE
  申请人：MERCK & CO INC

  公开号：WO2009102574A1

  公开（公告）日：2009-08-20

  The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的化合物，它们是M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包含该化合物的制药组合物，以及在治疗M1受体介导的疾病中使用该化合物和组合物的用途。
• OXADIAZOLE COMPOUND AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：SHANGHAI JIAO TONG UNIVERSITY

  公开号：US20140350026A1

  公开（公告）日：2014-11-27

  The present invention provides an anti-Coxsackie virus oxadiazole compound as represented by formula (I), or the pharmaceutically acceptable salt thereof, a preparation method, a pharmaceutical composition, and use thereof, wherein R is CH3 or CF3; R′ and R″ are respectively H, alkyl or halogen; A is O or S; n is a number from 1 to 6; X is O, S or NH; Y is alkyl, unsubstituted cycloalkyl, mono-substituted cycloalkyl, disubstituted cycloalkyl, poly-substituted cycloalkyl, unsubstituted aryl, mono-substituted aryl, disubstituted aryl, poly-substituted aryl, unsubstituted 5-6 membered heterocyclyl, mono-substituted 5-6 membered heterocyclyl, disubstituted 5-6 membered heterocyclyl, or poly-substituted 5-6 membered heterocyclyl. Compared to prior art, the oxadiazole compound of the present invention has excellent anti-Coxsackie virus activity, lower toxicity and high safety.

  本发明提供了一种抗柯萨奇病毒的噁二唑化合物，其化学式为（I）或其药学上可接受的盐，以及其制备方法、制药组合物和用途。其中，R为CH3或CF3；R'和R"分别为H、烷基或卤素；A为O或S；n为1至6的数字；X为O、S或NH；Y为烷基、未取代的环烷基、单取代的环烷基、双取代的环烷基、多取代的环烷基、未取代的芳基、单取代的芳基、双取代的芳基、多取代的芳基、未取代的5-6元杂环基、单取代的5-6元杂环基、双取代的5-6元杂环基或多取代的5-6元杂环基。与现有技术相比，本发明的噁二唑化合物具有优异的抗柯萨奇病毒活性，毒性较低，安全性高。
• METHODS FOR TREATING HEPATITIS C
  申请人：Karp Gary Mitchell

  公开号：US20100099672A1

  公开（公告）日：2010-04-22

  In accordance with the present invention, compounds that can inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.

  根据本发明，已经确定了可以抑制病毒复制的化合物，优选是乙型肝炎病毒（HCV）的复制，并提供了其使用的方法。在本发明的一个方面中，提供了用于治疗或预防病毒感染的化合物。在本发明的另一个方面中，提供了用于治疗或预防乙型肝炎病毒感染的化合物。